3 years 2.86
Extreme 2.8647
20.12
5 years 2.86
Extreme 2.8647
56.18
10 years 2.86
Extreme 2.8647
78
Manager TitleAgeSince
President - 2025-07-24
Date Insider Type Main position Quantity % Market Cap. Importance
7/25/25 Tender

Chief Technology Officer

538,331 0.6358%
7/25/25 Tender

Chief Administrative Officer

534,066 0.6308%
7/25/25 Tender

Founder

3,397,141 4.0125%
Logo VERE THER
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.
Employees
274
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - VERE THER
  1. Stock Market
  2. Stocks
  3. VERV Stock